Stress reduction, meditation and mindfulness program in patients with chronic Heart failure
- Conditions
- C10.886Heart failureStress, PsychologicalSleep Wake DisordersDepressive Disorder, Anxiety DisordersF03.080F03.600.300F01.145.126.990
- Registration Number
- RBR-7pzcyk
- Lead Sponsor
- niversidade Federal Fluminense
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
HF NYHA class I or II; literate, owners of an audio device for listening the meditation CD; committed adhering to 8 weeks of the program; with Mini Mental score beyond 16
Concomitant participation in another study or therapy involving mind body or drug intervention in the last month; Recent clinical decompensation with hospitalization or changes in medication prescription for HF in the last month; Surgery or percutaneous intervention planned for the next year; Presence of acute coronary syndrome or acute myocardial infarction within the last 2 months; Clinically significant valve disease; Acute myocarditis; Musculoskeletal diseases that prevented functional tests such as the 6 minute walk test
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Impact in perceived Stress (Perceived stress scale PSS-14), Anxiety (State-trace anxiety scale), Depression (Beck Depression Inventory-II) and Mindfulness (Freiburg mindfulness inventory).;Significant reduction in Stress Perception Scores by 37.3% and improvement in the score for mindfulness by 10%. Positive trends in reducing anxiety and depression but without statistical significance.
- Secondary Outcome Measures
Name Time Method Impact in Quality of life (Minnesota Living with Heart Failure questionnaire), sleep quality ( Pittsburgh Sleep Quality Index), functional capacity (6-minute walk test), inflammatory (IL1, IL6, TNF-alfa, RCP and ESR) and neuro-hormonal (NT-proBNP, Cortisol, Adrenaline and Noradrenaline) panels.;Significant improvement in quality of life by of 40%, in quality of sleep by 35.2%, in functional capacity by 22% and smaller increase in cortisol levels (16% vs 19%), without significant changes in the other biomarkers.